Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Takeda Pharmaceutical Co Ltd to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of September 30, 2025. This document discloses equity securities held by the company, specifically focusing on positions in biotechnology and healthcare-related firms.
Key Financial Metrics and Holdings
The filing details specific equity positions rather than Takeda's consolidated financial performance (revenue, profit, or cash flow). The following table summarizes the reported holdings:
| Issuer Name | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Ovid Therapeutics, Inc. | 7,475,000 | $5,750,000 | Discretionary |
| Ovid Therapeutics, Inc. | 2,316,595 | $1,781,996 | Sole |
| Equillium, Inc. | 2,609,717 | $1,824,977 | Discretionary |
| Xilio Therapeutics, Inc. | 1,243,084 | $1,475,121 | Discretionary |
| Shattuck Labs, Inc. | 1,232,329 | $515,619 | Discretionary |
| Rani Therapeutics Holdings, Inc. | 101,554 | $203,190 | Discretionary |
| American Well Corporation | 478,061 | $77,733 | Discretionary |
| Lyell Immunopharma, Inc. | 891,365 | $54,887 | Discretionary |
| Standard Biotools, Inc. | 21,470 | $16,515 | Discretionary |
Note: The filing text does not provide Takeda's consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It only reports the value of specific equity investments.
Material Changes
The filing text does not provide comparative data from the prior reporting period. Therefore, material changes in holdings or values versus the previous quarter cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F filing does not contain management commentary, financial guidance, outlook, or specific risk factors regarding Takeda's operations. It is a regulatory disclosure of investment holdings. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Key Facts for Investor Verification
- Investment Focus: Takeda holds significant positions in early-stage or specialized biotechnology companies (e.g., Ovid Therapeutics, Equillium, Xilio Therapeutics).
- Largest Position: The largest reported holding by value is in Ovid Therapeutics, Inc., with a combined value of approximately $7.53 million across two entries.
- Voting Rights: Most positions are held with "Discretionary" voting authority, except for a portion of the Ovid Therapeutics stake held with "Sole" authority.
- Data Limitation: This document does not reflect Takeda's overall financial health, only a snapshot of specific equity assets held as of September 30, 2025.